Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.

Antimicrobial agents and chemotherapy - 1 Dec 2011

Driscoll Timothy A, Frangoul Haydar, Nemecek Eneida R, Murphey Donald K, Yu Lolie C, Blumer Jeffrey, Krance Robert A, Baruch Alice, Liu Ping

Abstract excerpt

The current voriconazole dosing recommendation in adolescents is based on limited efficacy and pharmacokinetic data. To confirm the appropriateness of dosing adolescents like adults, a pharmacokinetic study was conducted in 26 immunocompromised adolescents aged 12 to <17 years following intravenous (IV) voriconazole to oral switch regimens: 6 mg/kg IV every 12 h (q12h) on day 1 followed by 4 mg/kg IV q12h, then...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to Immunocompromised Host

Share to Injections, Intravenous

Share to Liver Function Tests

Share to Triazoles

Share to Voriconazole

Source

Open in PubMed Open full text

Identifiers

PMID: 21911570
DOI: 10.1128/AAC.05010-11
PMCID: PMC3232803

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.PMID 21911570Read ↗

Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.Semantic proximity Read ↗

Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.Semantic proximity Read ↗

Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.Semantic proximity Read ↗

Possibly Appropriate Maintenance dose of Voriconazole in pediatric patients: a single center observational studySemantic proximity Read ↗

Highly Variable Plasma Concentrations of Voriconazole in Pediatric Hematopoietic Stem Cell Transplantation PatientsSemantic proximity Read ↗

Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections.Semantic proximity Read ↗

CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children after Hematopoietic Cell Transplantation.Semantic proximity Read ↗

Population pharmacokinetic analysis of voriconazole from a pharmacokinetic study with immunocompromised Japanese pediatric subjects.Semantic proximity Read ↗

Population Pharmacokinetics and Factors Influencing Trough Concentration of Voriconazole in Children with Hematological MalignanciesSemantic proximity Read ↗

Model-Oriented Dose Optimization of Voriconazole in Critically Ill Children.Semantic proximity Read ↗

Impact of CYP2C19 Phenotype and Drug-Drug Interactions on Voriconazole Concentration in Pediatric Patients.Semantic proximity Read ↗

Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.